Articles dans des revues avec comité de lecture (154)
  1. 35. Caravita, S., Faini, A., Deboeck, G., Bondue, A., Naeije, R., Parati, G., & Vachiery, J.-L. (2017). Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component. The Journal of heart and lung transplantation, 36(7), 754-762. doi:10.1016/j.healun.2016.12.011
  2. 36. Vachiery, J.-L. (2017). Treatment of pulmonary arterial hypertension in Eisenmenger syndrome: Practice makes (almost) perfect. The Journal of heart and lung transplantation, 36(4), 376-377. doi:10.1016/j.healun.2016.12.008
  3. 37. Vachiery, J.-L., Langley, J., Galie, N., Hoeper, M. M., Peacock, A. J., Sitbon, O., Cheli, M., Church, C., Olsson, K. K., Palazzini, M., & Waterhouse, B. (2017). Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. The Journal of heart and lung transplantation, 36(4), 399-406. doi:10.1016/j.healun.2016.04.013
  4. 38. Caravita, S., & Vachiery, J.-L. (2016). Obstructive Ventilatory Disorder in Heart Failure—Caused by the Heart or the Lung? Current heart failure reports, 13(6), 310-318. doi:10.1007/s11897-016-0309-5
  5. 39. Mehta, S., & Vachiery, J.-L. (2016). Pulmonary hypertension: The importance of correctly diagnosing the cause. European respiratory review, 25(142), 372-380. doi:10.1183/16000617.0104-2016
  6. 40. Hoeper, M. M., White, R. J., Miller, K. K., Langley, J., Harris, J. H. N., Blair, C., Rubin, L., Vachiery, J.-L., McLaughlin, V., Barberà, J. A., Frost, A., Ghofrani, H. A., Peacock, A. J., Simonneau, G., Rosenkranz, S., & Oudiz, R. J. (2016). Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. The Lancet Respiratory Medicine, 4(11), 894-901. doi:10.1016/S2213-2600(16)30307-1
  7. 41. Vicenzi, M., Deboeck, G., Faoro, V., Vachiery, J.-L., & Naeije, R. (2016). Response to the letter "Pulmonary artery wedge pressure and exercise oscillatory ventilation in pre-capillary pulmonary hypertension". International journal of cardiology, 204, 12. doi:10.1016/j.ijcard.2015.11.140
  8. 42. Caravita, S., Deboeck, G., Vachiery, J.-L., & Naeije, R. (2016). Pulmonary arterial hypertension associated with a von Hippel-Lindau gene mutation. The Journal of heart and lung transplantation, 35(9), 1138-1139. doi:10.1016/j.healun.2016.07.002
  9. 43. Maruyama, H., Dewachter, C., Sakai, S., Belhaj, A., Rondelet, B., Remmelink, M., Vachiery, J.-L., Naeije, R., & Dewachter, L. (2016). Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cells. Life sciences, 159, 111-115. doi:10.1016/j.lfs.2016.05.018
  10. 44. Kanwar, M. M., Thenappan, T., & Vachiery, J.-L. (2016). Update in treatment options in pulmonary hypertension. The Journal of heart and lung transplantation, 35(6), 695-703. doi:10.1016/j.healun.2016.01.020
  11. 45. Rosenkranz, S., Gibbs, J. S. R. J., Wachter, R., De Marco, T., Vonk-Noordegraaf, A., & Vachiery, J.-L. (2016). Left ventricular heart failure and pulmonary hypertension. European heart journal, 37(12), 942-954. doi:10.1093/eurheartj/ehv512
  12. 46. Vachiery, J.-L. (2016). Cas clinique n° 2: Interactions cœur-poumons – hypertension pulmonaire et maladies cardiaques gauches. Revue des Maladies Respiratoires Actualites, 8(1), 15-19. doi:10.1016/S1877-1203(16)30045-3
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Suivant >>